聚乙二醇干扰素α-2a注射液联合利巴韦林片治疗脾栓塞术后丙型病毒性肝炎肝硬化的临床研究  

Clinical of of pegylated interferon α-2a injection combined with ribavarin tablets on hepatitis C virus-related cirrhosis patients after splenic embolization

作　　者：杜合娟[1] 蒋亦明[1] 杨崎恩[1] 陈仁芳[1] 陆宇红[1] 陈淼[1] 周学士[1] 曹弘[1] 

机构地区：[1]无锡市第五人民医院传染科,江苏无锡214005

出　　处：《中国临床药理学杂志》2017年第16期1523-1526,共4页The Chinese Journal of Clinical Pharmacology

基　　金：南京医科大学科技发展基金资助项目(2013NJMU195)

摘　　要：目的观察聚乙二醇干扰素α-2a注射液联合利巴韦林治疗脾栓塞术后丙型病毒性肝炎(HCV,丙肝)肝硬化患者的临床疗效和安全性。方法将64例脾栓塞术后丙肝肝硬化患者随机分为对照组32例和试验组32例。2组患者均给予口服利巴韦林片,每次300 mg,tid的治疗。对照组给予皮下注射重组人干扰素α-2b的方式,每次3 MU,隔日注射;试验组在对照组治疗的基础上,给予皮下注射聚乙二醇干扰素α-2a,每次180μg,每周1次。2组患者连续治疗12周。比较2组患者治疗前后HCV RNA阳性率、血常规相关参数,血清谷丙转氨酶(ALT)、谷草转氨酶(AST)水平变化,以及药物不良反应的发生情况。结果治疗前2组患者HCV RNA阳性率均为100%(32/32例),治疗后,试验组和对照组HCV RNA阳性率分别为53.13%(17/32例)和78.12%(25/32例),差异有统计学意义(P<0.05)。治疗后,试验组和对照组的ANC分别为(4.76±0.33)×10~9,(3.92±0.17)×10~9/L;PLT水平分别为(142.73±17.04)×10~9,(128.72±17.96)×10~9/L;WBC水平分别为(8.15±1.84)×10~9,(6.57±1.69)×10~9/L;ALT水平分别为(41.25±22.42),(60.12±21.89)U·L^(-1);AST水平分别为(33.67±18.46),(51.22±16.95)U·L^(-1);AST/ALT值分别为0.78±0.69,1.27±0.73,差异均有统计学意义(均P<0.05)。试验组的药物不良反应发生率为40.63%(13/32例),对照组发生的药物不良反应发生率为28.12%(9/32例),差异无统计学意义(P>0.05)。结论聚乙二醇干扰素α-2a联合利巴韦林治疗脾栓塞术后丙肝肝硬化患者可有效降低患者HCV RNA阳性率,改善患者体内血清AST、ALT水平,安全性高。Objective To analyze the effect and safety of profile pegy- lated interferon α - 2a （ PEG - IFN - α - 2a） combined with ribavarin on hepatitis C virus （HCV） - related cirrhosis patients after splenic embolization. Methods Sixty -four HCV patients who underwent splenic embolization were randomly divided into treatment group and control group （32 cases in each group ）. Control group was given subcutaneous injection of recombinant human interferon α -2b （rhlFN α -2b） every other day, and oral administration of ribavarin 300 mg three times a day; Treatment group did not only receive the treatment above, but also received subcutaneous injection pegylated interferon α-2a 180 μg once a week. Both groups were treated for 12 weeks.HCV RNA positive rate, blood routine parameters, serum alanine aminotransferase （ALT）, aspartate aminotransferase （AST） levels, and adverse drug reactions were compared between the two groups. Results Before treatment, HCV RNA positive rate of the two groups were both 100% （32/32 cases）, after treatment, HCV RNA positive rate of treat- ment group was 53.13% （17/32 cases） and that of and the control group was 78. 12% （25/32 cases）, the difference was statistically significant （P 〈 0. 05 ）. After treatment, the ANC of treatment group was （4.76 ± 0. 33 ） × 10^9/L and that of the control group was （3.92 ± 0. 17 ）× 10^9/L, PLT levels of treatment group was （ 142. 73 ± 17.04 ） x 109/L and that of and the control group was （128.72 ± 17.96）× 10^9/L, WBC levels of treatment group was （8.15 ± 1.84）× 10^9/L and that of and the control group was （6.57 ± 1.69× 10）^9/L, and the difference was statisti- cally significant （P 〈 0. 05 ）. After treatment, the ALT of the experimental group was 41.2 ± 22. 4U · L^- 1 and that of and the control group was （60. 1 ±21.9） U · L^- 1 ,AST levels of the experimental group was 33.67 ± 18.46U · L^-land that of and the control group was （51.22 ± 16.95）U · L^- 1 ; The AST/AL

关 键 词：聚乙二醇干扰素Α-2A 利巴韦林 丙型肝炎 

分 类 号：R978[医药卫生—药品]